Evidence map›Paper›PMID 37689055›Full record

ArticleMed (New York, N.Y.)2023

Translational roadmap for regenerative therapies of eye disease.

Leonard A Levin, Michael F Chiang, Michael A Dyer, Thomas N Greenwell, Clive N Svendsen, Santa J Tumminia, Russell N Van Gelder, Rachel O Wong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Med (New York, N.Y.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Transdermal Clonidine for Hypertension: An Underutilized Ally in the Modern Era.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Leonard A LevinDepartment of Ophthalmology and Visual Sciences, McGill University, Montreal, QC H3A2B4, Canada; Department of Neurology & Neurosurgery, McGill University, Montreal, QC H3A2B4, Canada. Electronic address: leonard.levin@mcgill.ca.
Michael F ChiangNational Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA; National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, USA.
Michael A DyerDepartment of Developmental Neurobiology, St. Jude's Research Hospital, Memphis, TN 38105, USA.
Thomas N GreenwellNational Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Clive N SvendsenBoard of Governors Regenerative Medicine Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA; Department of Biomedical Sciences, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA.
Santa J TumminiaNational Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Russell N Van GelderDepartment of Ophthalmology, University of Washington School of Medicine, Seattle, WA 98195, USA; Department of Biological Structure, University of Washington School of Medicine, Seattle, WA 98195, USA; Department of Pathology and Laboratory Medicine, University of Washington School of Medicine, Seattle, WA 98195, USA; Roger and Angie Karalis Johnson Retina Center, University of Washington School of Medicine, Seattle, WA 98195, USA.
Rachel O WongDepartment of Ophthalmology, University of Washington School of Medicine, Seattle, WA 98195, USA; Department of Biological Structure, University of Washington School of Medicine, Seattle, WA 98195, USA.

Funding

Cell-type– and developmental stage–specific regulation of gene expression in the retinaR01EY030180 · NEI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI DYER, MICHAEL A · 2020 to 2023
$1.8M
GENE EXPRESSION IN AXOTOMIZED RETINAL GANGLION CELLSR01EY012492 · NEI · UNIVERSITY OF WISCONSIN MADISON · PI LEVIN, LEONARD A · 2000 to 2004
$1.2M
Novel Mitochondrial Targeted Neuroprotectants for GlaucomaR21EY017970 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI LEVIN, LEONARD A · 2007 to 2009
$607k
Development of redox-active therapies for ischemic optic neuropathyR21EY025074 · NEI · UNIVERSITY OF WISCONSIN-MADISON · PI LEVIN, LEONARD A · 2015 to 2016
$421k
NEI NIH HHS R01 EY012492NEI NIH HHS R21 EY017970NEI NIH HHS R21 EY025074
6 · The paper itself

Abstract

The translation of regenerative therapies to neuronal eye diseases requires a roadmap specific to the nature of the target diseases, patient population, methodologies for assessing outcome, and other factors. This commentary focuses on critical issues for translating regenerative eye therapies relevant to retinal neurons to human clinical trials.

Indexed as

Eye DiseasesRetinal NeuronsHumansTranslations

Identifiers

PMID37689055
PMCPMC10793077

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.